BioCentury
ARTICLE | Company News

neuroFix Therapeutics, Medgenics deal

October 5, 2015 7:00 AM UTC

Medgenics acquired neuroFix for $2 million in cash and more than $481 million in potential milestones. neuroFix is eligible to receive $6 million in cash and stock upon the earlier of the completion of an undisclosed corporate milestone and March 31, 2016. neuroFix is also eligible to receive up to $450 million in development, regulatory and sales milestones related to NFC-1 and any new product developed by Medgenics to treat ADHD, plus tiered royalties. neuroFix is also eligible to receive a $25 million payment for each indication NFC-1 is approved for other than ADHD. ...